國立虎尾科技大學 |

Personalized Therapy for Multiple Myeloma

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Personalized Therapy for Multiple Myeloma/ edited by Saad Z. Usmani, Ajay K. Nooka.
其他作者:	Usmani, Saad Z.
面頁冊數:	IX, 178 p. 5 illus., 3 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology . -
電子資源:	https://doi.org/10.1007/978-3-319-61872-2
ISBN:	9783319618722

Personalized Therapy for Multiple Myeloma
Personalized Therapy for Multiple Myeloma[electronic resource] /edited by Saad Z. Usmani, Ajay K. Nooka. - 1st ed. 2018. - IX, 178 p. 5 illus., 3 illus. in color.online resource.

Risk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.

This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.

ISBN: 9783319618722

Standard No.: 10.1007/978-3-319-61872-2doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Personalized Therapy for Multiple Myeloma
LDR:03054nam a22003975i 4500 001 998171
003 DE-He213
005 20200630011937.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319618722 $9 978-3-319-61872-2
024 7 $a 10.1007/978-3-319-61872-2 $2 doi
035 $a 978-3-319-61872-2
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Personalized Therapy for Multiple Myeloma $h [electronic resource] / $c edited by Saad Z. Usmani, Ajay K. Nooka.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a IX, 178 p. 5 illus., 3 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Risk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.
520 $a This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.
650 0 $a Oncology . $3 1253469
650 0 $a Hematology. $3 645254
650 1 4 $a Oncology. $3 593951
700 1 $a Usmani, Saad Z. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1289630
700 1 $a Nooka, Ajay K. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1289631
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319618715
776 0 8 $i Printed edition: $z 9783319618739
776 0 8 $i Printed edition: $z 9783319871820
856 4 0 $u https://doi.org/10.1007/978-3-319-61872-2
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)